Patents by Inventor Mathieu Blery

Mathieu Blery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NKp46 binding agents
    Patent number: 12365731
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: July 22, 2025
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 12037392
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • NKp46 binding agents
    Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 11225519
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 18, 2022
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10870700
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 22, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Denis, Carine Paturel, Nicolai Wagtmann
  • MICA BINDING AGENTS
    Publication number: 20200299380
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10711063
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 10676523
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: June 9, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Mica binding agents
    Patent number: 10577416
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 3, 2020
    Assignee: Innate Pharma, S.A.
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
    Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • Treatment of peripheral T cell lymphoma
    Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 10329348
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 25, 2019
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • Compositions and methods for treating proliferative disorders
    Patent number: 9447185
    Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: September 20, 2016
    Assignees: INNATE PHARMA, S.A., UNIVERSITY OF GENOVA, NOVO NORDISK A/S
    Inventors: Francois Romagne, Alessandro Moretta, Mathieu Blery, Petrus Johannes Louis Spee, Ulrik Morch
  • MICA BINDING AGENTS
    Publication number: 20150191542
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 7, 2013
    Publication date: July 9, 2015
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Compositions and Methods for Treating Proliferative Disorders
    Publication number: 20080274047
    Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
    Type: Application
    Filed: October 13, 2006
    Publication date: November 6, 2008
    Applicants: INNATE PHARMA, UNIVERSITA DI GENOVA, NOVO NORDISK A/S
    Inventors: Francois Romagne, Alessandro Moretta, Mathieu Blery, Petrus Johannes Louis Spee, Ulrik Morch
  • Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
    Publication number: 20080196111
    Abstract: The present invention relates to expression constructs and methods of specifically marking NK cells in nonhuman mammals. Specifically, methods are presented that allow the specific expression of foreign genes in the NK cells of a nonhuman mammal. Such methods are useful for the generation of animal models for disorders involving NK cells, and for the evaluation of genes or compounds with respect to their effects on NK cells.
    Type: Application
    Filed: March 17, 2006
    Publication date: August 14, 2008
    Applicant: Innate Pharma S.A.
    Inventors: Eric Vivier, Mathieu Blery, Thierry Walzer